Annexon, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

30 Mar 2026

ANNX

10-K: Annexon files 10-K, advances GBS, GA programs

Annexon posted a $206.7M 2025 net loss, filed an EMA MAA for GBS, guided to a 2026 U.S. BLA and GA Phase 3 topline in 4Q26, and added a new $150M ATM financing facility.

NASDAQ

3 Mar 2025

ANNX

Annexon, INC

10-K: Annexon's 10-K Filing: GBS Program Nears BLA Submission, GA Trial Progresses

Annexon's 10-K filing highlights progress in its GBS program with a planned BLA submission in early 2025 and the advancement of its GA trial, while reporting a net loss of $138.2 million for 2024.

NASDAQ

26 Mar 2024

ANNX

Annexon, INC

10-K: Annexon Inc. Files 10-K, Highlights Progress in Clinical Programs

Annexon Inc.'s 10-K filing details the company's financial status and progress in developing treatments for complement-mediated diseases, including Guillain-Barr Syndrome (GBS) and Geographic Atrophy (GA).